Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) for Use of Serogroup B Meningococcal (MenB) Vaccines in Adolescents and Young Adults (Including College Students)
MMWR recomm. rep; 64 (41), 2015
Two serogroup B meningococcal (MenB) vaccines have recently been licensed for use in the U.S. (MenB-FHbp [Trumenba, Wyeth Pharmaceuticals, Inc.] and MenB-4C [Bexsero, Novartis Vaccines]). Both vaccines were approved for use in persons aged 10 through 25 years. MenB-FHbp was licensed as a three-dose serie...